Company intelligence / Profile preview

ANGLE

Guildford, Surrey, United Kingdomwpzoom.com ↗

Ownership: Private
Development stage: Commercial

Overview

ANGLE is a leading liquid biopsy company specializing in the capture and analysis of circulating tumour cells using its proprietary Parsortix platform, which has received FDA clearance. The company's technology enables minimally invasive assessment of biomarkers such as androgen receptor status from blood samples, supporting oncology drug development, clinical trials, and translational research globally. Recent partnerships include an agreement with AstraZeneca to develop an androgen receptor detection assay for prostate cancer studies using the Parsortix system.

Therapeutic areas: Oncology
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

AstraZeneca

Beyond the preview

Go deeper on ANGLE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANGLE.

Explore the full profile